On January 18, 2017, a phase-I study in the therapeutic area of Tourette’s syndrome was started. The PI is the internationally renowned Tourette’s expert, Professor Kirsten Müller-Vahl of the Department of Psychiatry, Social Psychiatry and Psychotherapy of the Hannover Medical School (MHH), conducting this study in collaboration with the MHH team for early-phase clinical trials and drug research (Professor Christoph Schindler) at the CRC Hannover. This means that for the first time in a long while, a drug with a completely new mode of action for treating Tourette’s syndrome has reached the stage of clinical development. The candidate drug inhibits degradation of the body’s own cannabinoids, also referred to as endocannabinoids, thereby increasing their efficacy. The clinical efficacy of the new drug under investigation is similar to that of THC-based therapeutics, but it lacks their main side effects dizziness and drowsiness. Given that numerous scientific findings suggest clinical efficacy of cannabis and cannabis-based drugs in the treatment of Tourette’s syndrome, the candidate drug is being evaluated in a clinical trial to determine whether its tic-reducing efficacy is comparable to that of THC, while having a considerably more favorable profile of side effects.
Besides contributing to the development of a novel treatment option for Tourette’s syndrome, study participants benefit from the state-of-the-art research infrastructure for early-phase clinical trials in the Clinical Research Center Hannover.
Would you like to participate in this study?
For further information, please contact the study center in Hannover at telephone +49 511 5350-8333 or write us an e-mail.